These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

576 related items for PubMed ID: 23998969

  • 1. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
    Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH.
    Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
    [Abstract] [Full Text] [Related]

  • 2. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
    Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH.
    J Clin Lipidol; 2014 Sep; 8(1):94-106. PubMed ID: 24528690
    [Abstract] [Full Text] [Related]

  • 3. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
    Dunbar RL, Nicholls SJ, Maki KC, Roth EM, Orloff DG, Curcio D, Johnson J, Kling D, Davidson MH.
    Lipids Health Dis; 2015 Sep 02; 14():98. PubMed ID: 26328624
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN, COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.
    Clin Ther; 2007 Jul 02; 29(7):1354-67. PubMed ID: 17825687
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.
    Mozaffarian D, Maki KC, Bays HE, Aguilera F, Gould G, Hegele RA, Moriarty PM, Robinson JG, Shi P, Tur JF, Lapointe JF, Aziz S, Lemieux P, TRILOGY (Study of CaPre in Lowering Very High Triglycerides) investigators.
    JAMA Netw Open; 2022 Jan 04; 5(1):e2141898. PubMed ID: 34989797
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Jun JE, Jeong IK, Yu JM, Kim SR, Lee IK, Han KA, Choi SH, Kim SK, Park HK, Mok JO, Lee YH, Kwon HS, Kim SH, Kang HC, Lee SA, Lee CB, Choi KM, Her SH, Shin WY, Shin MS, Ahn HS, Kang SH, Cho JM, Jo SH, Cha TJ, Kim SY, Won KH, Kim DB, Lee JH, Lee MK.
    Diabetes Metab J; 2020 Feb 04; 44(1):78-90. PubMed ID: 31237134
    [Abstract] [Full Text] [Related]

  • 7. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
    Morton AM, Furtado JD, Lee J, Amerine W, Davidson MH, Sacks FM.
    J Clin Lipidol; 2016 Feb 04; 10(6):1442-1451.e4. PubMed ID: 27919362
    [Abstract] [Full Text] [Related]

  • 8. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
    Offman E, Marenco T, Ferber S, Johnson J, Kling D, Curcio D, Davidson M.
    Vasc Health Risk Manag; 2013 Feb 04; 9():563-73. PubMed ID: 24124374
    [Abstract] [Full Text] [Related]

  • 9. N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial.
    Dogay Us G, Mushtaq S.
    Lipids Health Dis; 2022 Sep 01; 21(1):84. PubMed ID: 36050695
    [Abstract] [Full Text] [Related]

  • 10. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial.
    Stroes ESG, Susekov AV, de Bruin TWA, Kvarnström M, Yang H, Davidson MH.
    J Clin Lipidol; 2018 Sep 01; 12(2):321-330. PubMed ID: 29289538
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.
    Am J Cardiol; 2012 Oct 01; 110(7):984-92. PubMed ID: 22819432
    [Abstract] [Full Text] [Related]

  • 12. Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia.
    Davidson MH, Phillips AK, Kling D, Maki KC.
    Expert Rev Cardiovasc Ther; 2014 Sep 01; 12(9):1045-54. PubMed ID: 25089906
    [Abstract] [Full Text] [Related]

  • 13. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
    Roth EM, Bays HE, Forker AD, Maki KC, Carter R, Doyle RT, Stein EA.
    J Cardiovasc Pharmacol; 2009 Sep 01; 54(3):196-203. PubMed ID: 19597368
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.
    Kim CH, Han KA, Yu J, Lee SH, Jeon HK, Kim SH, Kim SY, Han KH, Won K, Kim DB, Lee KJ, Min K, Byun DW, Lim SW, Ahn CW, Kim S, Hong YJ, Sung J, Hur SH, Hong SJ, Lim HS, Park IB, Kim IJ, Lee H, Kim HS.
    Clin Ther; 2018 Jan 01; 40(1):83-94. PubMed ID: 29223557
    [Abstract] [Full Text] [Related]

  • 15. Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study.
    Dunbar RL, Gaudet D, Davidson M, Rensfeldt M, Yang H, Nilsson C, Kvarnström M, Oscarsson J.
    Lipids Health Dis; 2020 May 30; 19(1):117. PubMed ID: 32473640
    [Abstract] [Full Text] [Related]

  • 16. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
    Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Pedersen TR, Ridker PM, Ray K, Karlson BW, Lundström T, Wolski K, Nissen SE.
    Clin Cardiol; 2018 Oct 30; 41(10):1281-1288. PubMed ID: 30125052
    [Abstract] [Full Text] [Related]

  • 17. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
    Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR.
    Am J Cardiol; 2008 Aug 15; 102(4):429-33. PubMed ID: 18678300
    [Abstract] [Full Text] [Related]

  • 18. A Single-dose, Comparative Bioavailability Study of a Formulation containing OM3 as Phospholipid and Free Fatty Acid to an Ethyl Ester Formulation in the Fasting and Fed States.
    Lapointe JF, Harvey L, Aziz S, Jordan H, Hegele RA, Lemieux P.
    Clin Ther; 2019 Mar 15; 41(3):426-444. PubMed ID: 30799231
    [Abstract] [Full Text] [Related]

  • 19. N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.
    Ide K, Koshizaka M, Tokuyama H, Tokuyama T, Ishikawa T, Maezawa Y, Takemoto M, Yokote K.
    Lipids Health Dis; 2018 Mar 15; 17(1):51. PubMed ID: 29544483
    [Abstract] [Full Text] [Related]

  • 20. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW, Lynch E.
    Postgrad Med; 2015 Mar 15; 127(8):869-73. PubMed ID: 26453247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.